Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. Financing When it comes to looking to the future in the drug discovery industry, an important question to ask is: Where is the money?

Antibody 98

Antibody Marketing Drugs Licensing 98

Pharmaceutical Technology

MARCH 9, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Tumour antibody serum compositions. The production of antibodies in response to proteins expressed during cancer development serves as a biomarker.

Antibody 147

Antibody Production Protein Regulation 147

Drug Discovery World

MARCH 12, 2024

DDW’s Megan Thomas speaks to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. Here, experts weigh in on the future of monoclonal antibodies (mAbs). Amanda Halford, President Bioprocess, Cytiva “In 2024, the emphasis will remain on novel mAbs, specifically antibody drug conjugates.

Antibody 81

Antibody FDA Approval Drugs Development 81

Drug Discovery World

MAY 21, 2024

Ben Holland , CTO and Co-Founder of Antiverse discusses how artificial intelligence and machine learning are benefitting antibody discovery and design. Modern experimental procedures, such as immunisation, B-cell screening, and synthetic library generation, have been pivotal in developing approximately 80 FDA-approved antibody therapeutics.

Antibody 59

Antibody Development FDA Approval Contract Manufacturing 59

XTalks

MAY 9, 2024

Genmab, a trailblazer in the field of antibody therapeutics, celebrates this milestone by reflecting on its impressive journey from a small-scale startup to a global leader in cancer treatment and beyond. Since then, innovative science has been at Genmab’s core, as we harness the power of human antibodies to improve the lives of patients.

Antibody 52

Antibody Clinical Trials Clinical Trials Medicine 52

Pharmaceutical Technology

AUGUST 5, 2022

As per the prevailing prion theory, a misfolded version of a normal cell-surface protein acts as the chief infectious agent. It is ultra-rare,” says Jesús Rodriguez Requena, PhD, associate professor in the Department of Medicine at the University of Santiago de Compostela. No progress in drug discovery. “We

Drugs 299

Drugs Protein Vaccination Vaccine 299

XTalks

DECEMBER 12, 2023

Plasma medicine is a critical and specialized field within healthcare, centering on the use of human plasma for the development and administration of life-saving treatments. Human plasma, the clear, liquid portion of blood, is composed of water, electrolytes, nutrients and crucial proteins such as antibodies, clotting factors and albumin.

Medicine 111

Medicine Recombinant Antibody Protein Antibody 111

pharmaphorum

MAY 30, 2022

pharmaphorum sat down with Sunil Verma, global head of oncology, medical, at AstraZeneca, to discuss three studies that were presented at the show, which demonstrate a few of the ways oncology is advancing through precision medicine and targeted therapies. That antibody-drug conjugate then docks on the cancer cell receptor.

Antibody 110

Antibody Drugs Medicine Research 110

Drug Discovery World

JANUARY 24, 2024

Three different HIV antibodies each independently protected monkeys from acquiring simian-HIV (SHIV) in a placebo-controlled proof-of-concept study intended to inform development of a preventive HIV vaccine for people. In this study, rhesus macaques in each of four groups received a single intravenous infusion of one type of antibody – a 2.5

Antibody 52

Antibody Vaccination Vaccine Allergies 52

Drug Discovery World

JULY 24, 2023

The Defense Advanced Research Projects Agency (DARPA) has announced that Ginkgo Bioworks, which is building a platform for cell programming and biosecurity, has been awarded a four-year contract worth up to $18 million to reimagine how to manufacture complex therapeutic proteins.

Protein 52

Protein Manufacturing Gene Sequencing Production 52

BioPharma Reporter

OCTOBER 24, 2022

AbbVie will acquire DJS Antibodies Ltd, a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins.

Antibody 45

Antibody Protein Medicine Development 45

XTalks

FEBRUARY 29, 2024

Dual-function fusion proteins represent a cutting-edge approach in biopharmaceutical research, offering a promising avenue for the development of novel therapeutics in the treatment of complex diseases such as cancer and autoimmune disorders. My initial exposure to medicine came through bench research.

Protein 94

Protein Development Clinical Trials Clinical Trials 94

Drug Discovery World

FEBRUARY 7, 2024

Professor Jonathan Blackburn, Chief Scientific Officer (CSO) of Sengenics, featured in a sponsored DDW Sitting Down With podcast to discuss the advantages of functional protein microarrays, challenges to overcome for biomarker discovery, Sengenics’ new i-Ome Discovery chip, and more. Sengenics can also help comb through all the data.

Medicine 59

Medicine Protein FDA Approval DNA 59

Drug Discovery World

JANUARY 25, 2024

US company Vaxxinity and the University of Central Florida (UCF) have announced plans to work together to advance space medicine research. Vaxxinity’s platform is designed to harness and selectively activate the immune system by overcoming immune tolerance, stimulating the production of antibodies against endogenous targets.

Medicine 52

Medicine Research In-Vivo In-Vitro 52

Drug Discovery World

JULY 24, 2023

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended conditional marketing authorisation for Janssen’s Talvey (talquetamab). The post CHMP recommendation for bispecific antibody talquetamab appeared first on Drug Discovery World (DDW).

Antibody 52

Antibody Licensing Licensing Medicine 52

Pharmaceutical Technology

JANUARY 4, 2023

The China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) has granted clearance for Transcenta’s investigational new drug (IND) application for its TST003 to treat solid tumours. TST003 is a first-in-class Gremlin1 targeting humanised monoclonal antibody.

Antibody 242

Antibody In-Vivo In-Vitro Protein 242

Drug Discovery World

APRIL 25, 2024

Xaira is building a platform for drug discovery and development that it hopes will advance multiple drug programmes and unlock biological understanding to inform future discovery. It employs a group of researchers who developed the leading models for protein and antibody design, RFdiffusion and RFantibody, while in Dr Baker’s lab.

Drugs 52

Drugs Protein Antibody Engineer 52

Pharmaceutical Technology

MAY 15, 2023

Chinese biotech company LaNova Medicines and AstraZeneca have entered an exclusive licence deal for La Nova’s LM-305. LM-305 is a new pre-clinical stage antibody-drug conjugate (ADC) that targets G protein-coupled receptor, class C, group 5, member D (GPRC5D).

Medicine 130

Medicine Antibody Development Drugs 130

Pharma Mirror

OCTOBER 6, 2021

The rising need for early diagnosis of chronic diseases, coupled with growing demand for drugs which work better and have fewer side effects, is largely responsible for the growth of the protein A resin market. Chromatography requires an antibody to bind to a protein A resin.

Research 130

Research Protein Antibody Manufacturing 130

XTalks

MARCH 31, 2023

BMS researchers on the mission will study the crystallization of an assortment of their biologics medicines in microgravity. By growing high quality crystal structures of protein-based therapeutics under microgravity, researchers can gain better insights into their complex structures and stability.

Protein 97

Protein Research Development Manufacturing 97

XTalks

JULY 25, 2022

Byondis announced that the US Food and Drug Administration (FDA) accepted their Biologics License Application (BLA) for [vic-]trastuzumab duocarmazine (SYD985), an investigational therapy being studied to treat HER2-positive unresectable locally advanced or metastatic breast cancer. Treating HER2-Positive Metastatic Breast Cancer.

Antibody 59

Antibody Drugs Clinical Trials Clinical Trials 59

Pharmaceutical Technology

JUNE 15, 2023

Confo Therapeutics and AbCellera have entered a research partnership to discover GPCR [specific G protein-coupled receptor ligand]-targeting antibody candidates. The collaboration will use Confo Therapeutics’ suite of ConfoBody-enabled antibody discovery technologies on two undisclosed GPCR targets.

Antibody 130

Antibody Sales Protein Development 130

Drug Discovery World

NOVEMBER 15, 2022

Anita Ramanathan outlines four synthetic biology approaches that are improving and accelerating drug discovery. . It has made its way into almost every aspect of drug discovery, whether it’s exploring basic biology, modelling diseases, identifying and validating targets, or performing drug screens. .

DNA 98

DNA Drugs Antibody Engineer 98

Roots Analysis

MAY 11, 2022

Over the years, the drug hunters have tried to target the tens of thousands of proteins responsible for sickness and health. In this article, we will evaluate the rising popularity of the concept of targeted protein degradation in overcoming the aforementioned challenges. What is Targeted Protein Degradation?

Protein 52

Protein Marketing Antibody Drugs 52

Pharmaceutical Technology

MARCH 14, 2023

Seagen discovers, develops, and commercialises transformative cancer medicines. It is a pioneer in antibody-drug conjugates (ADCs) technology. The company’s portfolio includes four approved medicines, including three ADCs, Adcetris (brentuximab vedotin), Padcev (enfortumab vedotin), and Tivdak (tisotumab vedotin).

Antibody 130

Antibody Medicine Engineer Protein 130

Drug Discovery World

APRIL 26, 2023

Absci is a generative artificial intelligence (AI) drug creation company with goals of bringing better biologics to patients more quickly. Here, DDW Editor Reece Armstrong speaks to Sean McClain, the Founder and CEO of Absci about how generative AI is being used within drug discovery and the company’s work in the antibodies sector.

Drugs 52

Drugs Antibody Protein Marketing 52

Pharmaceutical Technology

DECEMBER 16, 2022

Novartis and the non-profit Medicines for Malaria Venture (MMV) announced plans to collaborate on a Phase III study of a novel ganaplacide/lumefantrine-SDF combination for adults and children. Both vaccines are based on recombinant proteins and attack the parasite during the sporozoite stage.

Development 264

Development Drugs Vaccination Vaccine 264

Drug Discovery World

APRIL 3, 2024

In the last few years, immunotherapies like immune checkpoint inhibitors, vaccines and cell and gene therapies have revolutionised the treatment of cancer, and targeted drugs like monoclonal antibodies (mAbs), poly-ADP ribose polymerase (PARP) inhibitors and targeted protein degraders are also playing an important role.

Research 52

Research Drugs Gene Therapy Genetics 52

Drug Discovery World

APRIL 8, 2024

The two-year grant will be used to expand Confo’s R&D efforts in the discovery of new medicines targeting Class B G protein-coupled receptors (GPCRs) using its patent-protected technology platform. Class B GPCRs are recognised as important targets for new medicines, particularly in chronic endocrine and metabolic diseases.

Drugs 52

Drugs Medicine Protein Antibody 52

Pharmaceutical Technology

APRIL 20, 2023

Biopharmaceutical company Abdera Therapeutics has raised $142m in combined Series A and B financing to engineer and advance antibody-based radiopharmaceuticals to treat cancer. The company’s lead programme is aimed at delta-like ligand 3 (DLL3), which is a protein in the Notch pathway.

Antibody 130

Antibody Engineer Protein Drugs 130

The Pharma Data

APRIL 15, 2022

A new protein-based antiviral nasal spray developed by researchers at Northwestern University, University of Washington and Washington University at St. Designed computationally and refined in the laboratory, the new protein therapies thwarted infection by interfering with the virus’ ability to enter cells. Diamond at WashU.

Antibody 52

Antibody Protein Engineer Manufacturing 52

The Pharma Data

MARCH 31, 2023

i for CMG901, a potential first-in-class antibody drug conjugate (ADC) targeting Claudin 18.2, Notes CMG901 CMG901 is a novel antibody drug conjugate targeting Claudin 18.2, monoclonal antibody, a protease-degradable linker, and a cytotoxic small molecule monomethyl auristatin E (MMAE). million deaths.

Licensing 40

Licensing Licensing Antibody Drugs 40

Pharmaceutical Technology

FEBRUARY 19, 2023

According to GlobalData, Phase I drugs for Refractory Acute Myeloid Leukemia have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how STRO-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Antibody 100

Antibody Protein Clinical Development Manufacturing 100

Pharmaceutical Technology

MAY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Oxazole derivatives-based cancer drug compositions. They also inhibit tubulin protein to induce apoptosis in cancer cells.

Drugs 130

Drugs DNA Protein Antibody 130

Drug Discovery World

OCTOBER 20, 2023

The latest acquisitions and strategic partnerships in the drug discovery and development sector reveal the areas where companies predict significant growth in the near future: proteomics, CAR-T, antibody discovery, artificial intelligence (AI) and microbiomics. We aim to continue to ‘open up’ the druggable antibody space.”

Drugs 52

Drugs Antibody DNA Gene Therapy 52

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.

Antibody 64

Antibody Engineer Protein Scientist 64

Drug Discovery World

APRIL 3, 2023

I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development. What advantages do they offer over antibodies?   DS: How are aptamers currently used in the development of precision treatments?

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52